BioAge Labs (NASDAQ:BIOA) reported fourth‑quarter 2025 results on March 24, 2026, posting a net loss of $0.72 per share versus the consensus estimate of $0.73 per share, a 1.4% beat on earnings. The company generated $3.078 million in revenue, topping the $1.915 million estimate and marking a significant upside in sales.
The revenue beat was driven largely by collaboration income, which rose to $3.078 million from $2.1 million in Q3 2025. The company’s partnership with Novartis contributed $9.0 million in full‑year collaboration revenue, a jump from $0 in 2024, underscoring the growing value of its non‑clinical revenue streams. The stronger-than‑expected collaboration income helped offset the continued investment in research and development, which remained high as BioAge advances its lead candidate BGE‑102 into Phase 2a trials.
Compared with the prior quarter, the loss narrowed from $0.56 per share in Q3 2025, and the company’s cash position improved to $285.1 million as of December 31, 2025, giving an estimated runway through 2029. The company also completed an upsized public offering in early 2026 that raised $132.3 million, further strengthening its liquidity profile.
BioAge’s management highlighted the progress of BGE‑102, noting that interim Phase 1 data showed an 86% median reduction in hsCRP at 120 mg. The company plans to initiate a Phase 2a proof‑of‑concept trial in cardiovascular risk in the first half of 2026, positioning the drug for potential future commercialization. The earnings beat and revenue upside reinforce the company’s ability to fund ongoing pipeline development while maintaining a robust cash runway.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.